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Background: Human kallikrein-related peptidase 6 (KLK6) has been implicated in various types of cancer and in
neurodegenerative and demyelinating diseases including multiple sclerosis. Further, anti-KLK6 antibodies attenuated
disease manifestations in the mouse model of multiple sclerosis. Availability of specific antibodies against KLK6 is
fundamental to the development of improved diagnostic and/or immunotherapeutic applications. Here, we
exploited the enhanced immunogenicity of mammalian proteins in avian species to generate a polyclonal antibody
against KLK6.
Results: Chicken were immunized with recombinant KLK6 and antibodies Y (IgYs) were purified from egg yolk with
a simple procedure and evaluated for KLK6 detection by ELISA and Western blot using recombinant proteins and
human cell lysates and supernatants. The anti-KLK6 Y polyclonal exhibited high affinity for KLK6 with a detection
limit of 30 fmol. On the other hand, the widely used rabbit polyclonal antibody that was raised against the same
recombinant KLK6 had a detection limit of 300 fmol. Moreover, the IgYs did not display any crossreactivity with
recombinant KLKs or endogenous KLKs and other cellular proteins.
Conclusions: Based on its high specificity and sensitivity the developed anti-KLK6 IgY is expected to aid the
development of improved diagnostic tools for the detection of KLK6 in biological and clinical samples.
Keywords: Kallikrein-related peptidase 6(KLK6), IgY, ImmunoassaysBackground
Y antibodies are the predominant serum immunoglobulins
in birds, reptiles and amphibians. In the female, transfer of
IgYs from serum to egg yolk confers passive immunity to
embryos and neonates [1,2] similarly to placental IgG
transfer in mammals which also confers passive immunity
to the fetus. The enrichment of these immunoglobulins in
egg yolk led Leslie and Clem to name this antibody class
IgYs [3]. There are several advantages associated with the
development and usage of Y antibodies, including better
immune responsiveness to mammalian antigens, higher
affinity with persistent titer, non-invasive collection, sim-
ple and low cost isolation process, large yield and scalable
production [1], while enhanced immune response results
in antibodies with improved specificity and sensitivity as
compared to mammalian IgGs. In this study, we exploited* Correspondence: gdsotiro@upatras.gr
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distribution, and reproduction in any mediumthese advantages for the generation of a novel polyclonal
that recognizes the KLK6 protease with high affinity and
specificity.
KLK6 was originally identified and cloned based on its
aberrant expression in mammary and ovarian cancers
and was proposed as a potential diagnostic biomarker
[4]. Now it is known that KLK6 has a tissue-wide range
of expression, including breast, central nervous system,
kidney etc. [5]. It should be emphasized that KLK6 has
many transcript and splice variants [6,7]. Transcript var-
iants result from alternative promoters usage and encode
for the same KLK6 protein, since all mRNA sequence
changes occur at the 50-untranslated region, while splice
variants result mainly by skipping coding exons and they
either encode for small proteins with low identity to
KLK6 or to no proteins at all [6,7].
Recently, it was shown that stromal cell-associated ex-
pression of KLK6 is an indicator of poor prognosis in
ovarian cancer patients [8]. KLK6-positive ovarian can-
cer patients show an increased risk of relapse and deathCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,














Figure 1 Structure of IgYs. Representation of Y and G antibodies
[modified from 2].
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KLK6 and CA-125 enhances the diagnostic power [10].
Additionally, KLK6 has been found up-regulated both in
tumor specimens and serum of patients with colon cancer
and high KLK6 expression was associated with poor prog-
nosis [11]. Elevated expression of KLK6 in gastric cancers
as compared to noncancerous tissues was associated with
lymphatic invasion [12]. Finally, KLK6 shows strong ex-
pression in low grade in contrast to high grade renal cell
carcinomas [13] and represents a potential serum bio-
marker for uterine serous papillary cancer [14].
The role(s) of KLK6 in the progression of human malig-
nancies are not clear and they may vary with the type of
cancer and KLK6 levels of expression [15]. KLK6 has been
shown to cleave components of the extracellular matrix
(ECM), therefore it was concluded that KLK6 promotes
cancer invasion and metastasis [16]. In addition, KLK6
was shown to release angiostatin for plasminogen, thus it
may have anti-angiogenic potential [17]. In breast cancer
expression of KLK6 at physiological levels has tumor-
suppressor properties, while over-expression results in
tumor promotion [18]. Overexpression of KLK6 in lung
cancer is related to increase in cyclin E and increase in cell
proliferation [19].
KLK6 has also been suggested as a new biomarker for
neurodegenerative diseases. Specifically, plasma levels of
KLK6 were found reduced in patients with Alzheimer
disease or other forms of dementia compared to age-
related healthy individuals [20,21]. Further, KLK6 was
found elevated in the serum of multiple sclerosis
patients with highest levels being associated with sec-
ondary progressive disease [22]. On the other hand,
KLK6 can degrade myelin. Consequently, it is considered
to play important roles in the physiological demyelin-
ation and remyelination process [23,24], while its aber-
rant activity has been associated with pathological
demyelination typical of multiple sclerosis and other de-
myelinating diseases. Importantly, passive immunization
through administration of anti-KLK6 antibodies or active
immunization through administration of recombinant
rat Klk6, to induce the production of anti-KLK6 anti-
bodies, delayed significantly the onset and attenuated
the symptoms of experimental autoimmune encephalo-
myelitis (EAE), the mouse model for multiple sclerosis
[25]. Recently, Klk6 neutralizing antibodies slowed dis-
ease progression in the TMEV (Theiler’s murine enceph-
alomyelitis virus) mouse demyelination model [24]. Also,
KLK6 was shown to be new serum prognostic marker
for aneurismal subarachnoid hemorrhage. Specifically,
serum KLK6 was decreased in patients relative to adult
population and the lowest concentrations were corre-
lated with worse outcome [26].
On the other hand, a large body of emerging evidence
suggests that there is a functional interaction of KLKs,including KLK6, with proteases of the thrombostasis axis
[27]. Potential regulatory interaction between KLK6 and
proteases of the thrombostasis axis could have a large
impact in various human diseases, including neurode-
generation and cancer, as discussed above [27]. Conse-
quently, the development of new reagents for the
detection of KLK6 with potential diagnostic applications
is of great importance. Presently, a limited number of
rabbit polyclonal or mouse monoclonal antibodies have
been generated against KLK6. Often, their specificity (i.e.
lack of crossreactivity with other KLKs or non-KLK pro-
teins) has been debated. Using IgY technology, we devel-
oped a new polyclonal antibody that displayed high
specificity and sensitivity for KLK6 in Western blot and
ELISA immunoassays.
Results
Production of anti-KLK6 IgYs
Chicken were immunized with rKLK6, the laying eggs
were collected and IgYs were purified by a modification
of the acidified water procedure [28]. The structure of Y
antibodies resembles the structure of G antibodies ex-
cept for the longer Fc fragment (Figure 1) [2]. A major
difference between Y and G is the inability of Y anti-
bodies to bind to bacterial Fc receptors such as the
staphylococcal Protein A or streptococcal Protein G [1].
The purity of the generated IgYs was very high and no
contaminating proteins could be detected by SDS-PAGE
resolution of IgYs (data not shown). The two detected
bands of about ~67 kDa and 25 kDa correspond to the
heavy and light chains of IgYs, respectively. The 35 kDa
band of the vitellogenin II precursor observed in
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IgY production was 100 mg per single yolk, which is
substantially higher than yields for IgG production.
Titration and displacement ELISA
The developed IgYs were initially evaluated by ELISA.
As shown in Figure 2A, under the conditions used
(details in Materials and Methods section), the titer of
the obtained antibody was approximately 0.125 μg/ml
(negative controls either no coating or without IgYs gave
absorbance values between 0.402 and 0.509). More spe-
cifically, the 0.125 μg/ml concentration of the antibody
gave absorbance values >1.5-times the negative controls.
Figure 2B shows the displacement curves obtained for
the antibody. The addition of rKLK6 displaced bound






























Figure 2 Titration and displacement ELISAs. A, Antibody titer determinaAntibody characterization
The generated chicken anti-KLK6 antibody (IgYs) was
compared with a rabbit polyclonal against KLK6 that has
been widely used for analyses of biological and clinical
samples [5,21,29,30]. The sensitivity of IgYs and that of
the widely used rabbit polyclonal were compared in par-
allel by Western using serial dilutions of rKLK6. As
shown in Figure 3A, the detection limit of IgYs was down
to one ng or ~30 fmol of KLK6 compared to 300 fmol for
the rabbit polyclonal.
Then, we tested the potential crossreactivity of the pro-
duced IgYs with other recombinant KLKs that we had pro-
duced [17]. Recombinant KLK5 and KLK13, which is the
most closely related by sequence to KLK6 [31], were tested.
As shown in Figure 3B, no crossreactivity could be detected
even for high (1–1.5 μg) amounts of recombinant proteins.y = -0,2731x + 1,2498
R2 = 0,9798
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Figure 3 Sensitivity and specificity of IgYs. Recombinant and endogenous KLK6 were detected by Western blotting using IgYs at 1:2,500. A,
IgYs could detect as low as 1 ng (30 fmol) of rKLK6, while the widely used anti-KLK6 rabbit polyclonal [30] was limited to 10 ng (300 fmol). B, IgYs
could recognize rKLK6 (100 ng) but lacked crossreactivity with its most homologous KLK13 (rKLK13, 1.5 μg) but also KLK5 (rKLK5, 1 μg) (Western
blot, upper). Integrity of the loaded proteins was confirmed by Coomassie staining (SDS-PAGE gel, lower). C, IgYs lack crossreactivity with any of
the secreted proteins as no band could be detected in MDA-MB-231 cells that do not produce KLK6 (lane 1, left). A single band of 37 kDa
corresponding to endogenous KLK6 could be detected in MDA-MB-468 and MDA-MB-231 C5WT, a cDNA-transfected clone to stably express KLK6
[18] (lanes 2 and 3 respectively; left). Moreover, lack of crossreactivity of IgYs with other cellular proteins was confirmed by analysis of whole cell
lysates (100 μg) isolated from MDA-MB-231 C5WT (lane 1, right) and MDA-MB-468 (lane 3, right). Additionally, IgYs could recognize a mutant form
of KLK6 produced by MDA-MB-231 C7MS transfectants (lane 2, right) that lacks enzymatic activity [18]. D, Heat-induced denaturation of rKLK6
increases the sensitivity of IgYs. 5, 10 and 20 min refer to times of incubation at 95°C, while 5 and 10 sec denote the time of exposure; the two
bands correspond to glycosylated (31 kDa) and non-glycosylated (25 kDa) rKLK6 produced in Pichia pastoris.
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KLK6 and lack of crossreactivity with other KLKs and unre-
lated proteins was assessed by analyzing whole cell lysates
and supernatants isolated from MDA-MB-468 breast can-
cer cell line that expresses the KLK5, KLK6 and KLK10
proteins. The MDA-MB-231 KLK6-non-expressing cell line
was used as a negative control for KLK6 but a positive con-
trol for KLK1 [32]. In addition, cDNA-transfected MDA-
MB-231 cells with stably reconstituted KLK6 expression
were included in the analysis [18]. The IgYs could detect
the endogenous (secreted and intracellular) KLK6 protein
produced by MDA-MB-468 and MDA-MB-231 cells stably
transfected with the KLK6 cDNA (Figure 3C) and no other
proteins were detected indicating high specificity of IgYs for
detection of endogenous KLK6 by Westerns. On the other
hand, complete absence of crossreactivity of the anti-
KLK6 IgYs with endogenous KLK5 and KLK10 or any
other KLK-unrelated proteins could be demonstrated in
lysates and supernatants of MDA-MB-468. Also, lack of
crossreactivity with KLK1 was shown in MDA-MB-231
cells (Figure 3C). If KLK10 was detected in MDA-MB-468it would have given a band that would not overlap with
the KLK6 due to difference in molecular weight (30 kDa
for KLK10 compared to 37 kDa for glycosylated KLK6). In
addition, KLK6 protein was detected in differentiated SH-
SY5Y neuroblastoma cells, while other bands derived
from non-specific binding of IgYs could not be detected
(Vekrellis, Sotiropoulou et al. unpublished data).
Finally, we showed that denaturation of the KLK6
protein due to prolonged heating at 95°C enhanced the
sensitivity of IgYs against KLK6 (Figure 3D). This obser-
vation can be exploited in Westerns to reduce the detec-
tion limit of IgYs below the 1 ng (30 fmol) KLK6 threshold.
The generated IgYs were shown unable to immunoprecipi-
tate KLK6 (not shown), which is common for Y antibodies
due to their shorter hinge structure that usually renders
them less effective in immune-precipitations as compared
to G antibodies [1].
Effect of IgYs on KLK6 activity
IgYs were tested for inhibitory ability against the enzym-
atic activity of KLK6. As shown in Figure 4, partial
100
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Figure 4 Inhibition of KLK6 activity by IgYs. The activity was measured in the absence (A) and presence of IgYs at increasing molar ratios of
IgYs:rKLK6 equal to 1:1, 20:1 and 30:1 (B, C and D, respectively). Then, the trypsin substrate N-benzoyl-L-arginine ethyl ester (BAEE) was added and
the change in absorbance at A254 was measured relative to time for 3 min. The corresponding changes in the absorbance at A254 were
normalized and expressed % of the rKLK6 without addition of the antibodies. IgYs could inhibit rKLK6 only moderately as 61% of its activity
remained at a molar ratio as high as 30:1, while the E24 mouse monoclonal control could extinguish 60% of the activity at 1:1. Rates of hydrolysis
of the BAEE substrate by rKLK6 are shown. BAEE was used at 250 μΜ and rKLK6 at 12 nM.
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molar ratios IgYs:KLK6 as high as 30:1, indicative of a
small fraction of IgYs recognizing three-dimensional epi-
topes. Thus, it may still be possible to raise antibodies
with enzyme-inhibitory activity in avian species. The
well-described E24 mouse monoclonal that blocks the
enzymatic activity of KLK6 [16] was used as positive
control, which at molar ratio 1:1 caused about 60% in-
hibition of KLK6 activity. Allowing KLK6-IgYs complex
formation for longer time (10 min) did not increase fur-
ther the extent of inhibition (not shown).
Discussion
Despite the fact that IgYs were described about 120 year
ago their applications in immunoassays have been lim-
ited compared to IgGs [1]. In the recent years however,
the development of chicken antibodies is considered an
advantageous alternative compared to the classical mam-
malian immunization procedures, mainly because mam-
malian proteins exhibit enhanced immunogenicity in
avian species due to phylogenetic distance. Recently, the
so-called IgY technology was suggested as a potential
new way for passive immunization to treat human and
animal diseases [33].
We applied IgY technology to high-yield generation of Y
antibodies against rKLK6 that were purified to near homo-
geneity with a very simple and inexpensive procedure and
characterized in established immunochemical methods for
future validation in clinical diagnosis. The utility of our
anti-KLK6 Y antibodies lies in their absence of immuno-
logical crossreactivity with enzymes of the KLK family,specifically KLK5 and KLK13 and endogenous KLK1 and
KLK10, but also with any other cellular proteins produced
by mammary (and neuronal) cells, likely due to the evolu-
tionary distance between avian and human species. Lack
of specificity of anti-KLK antibodies, especially their cross-
reactivity with multiple KLKs, has been an obstacle to the
optimization of immunoassays for clinical applications.
Even the extensively used and characterized anti-KLK3
(PSA) antibodies (rabbit polyclonal and mouse monoclo-
nal antibodies) were shown to crossreact with KLK2 and
KLK1 [34]. Moreover, our IgY production offers the
advantages of easy scale-up to gram levels and simple
purification process. Generation of 100 mg of IgGs that
can be obtained from a single yolk, would require approxi-
mately 20 ml of rabbit antiserum [28].
Recently, an anti-peptide rabbit polyclonal was generated
against the KLK6 (109–119) region that lacks homology
with other KLKs, thus, the affinity-purified polyclonal dis-
played high specificity against KLK6 [8]. To the advantages
of our production method, high yield and no need for af-
finity purification should be added. Availability of adequate
amounts should facilitate pharmacological validation of
IgYs for potential therapeutic applications. Indeed, anti-
KLK6 therapy was effective in mouse models of multiple
sclerosis [23-25]. However, our antibody has certain limita-
tions in its applications. Specifically, we demonstrated that
the developed antibody cannot be used for immunopreci-
pitations which is a more general drawback of Y antibodies.
Further, it cannot be used as a potent inhibitor of KLK6
protease activity since it shows moderate inhibition and
only in high molecular ratios.
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of clinical or research immunochemical tests. Further it
reduces the number of animals used since a single hen
can produce eggs having the desired IgYs for at least
10 months leading to the production of very high
amounts of antibodies [2]. Finally, it meets the recom-
mendations of the European Centre for the Validation of
Alternative Methods (ECVAM) that specifies that IgYs
are suggested to be used instead of mammalian anti-
bodies for animal welfare purposes [35]. To our know-
ledge this is the first study that develops a chicken
antibody against KLK6 and in general against a member
of the human KLK family of serine proteases.Conclusions
This study generated a novel chicken polyclonal antibody
against KLK6. KLK6 is an emerging new biochemical mar-
ker for clinical diagnosis of various forms of cancer, in-
cluding ovarian cancer and for neurodegerative disorders.
The developed antibody exhibited sensitivity in the subpi-
comolar range and very importantly it lacked crossreactiv-
ity with other KLK enzymes or cellular proteins.Methods
Materials
All chemicals used were obtained from Sigma (St. Louis,
MO, USA) or Merck (Darmstadt, Germany).Production of recombinant KLKs
Recombinant KLK6 (rKLK6) and other recombinant KLKs
were produced in the methylotrophic yeast Pichia pastoris
KM71 strain, purified to homogeneity and activity-tested
as described [15,36,37]. The identity of the proteins was
verified by N-terminal analysis by Edman degradation
and/or MALDI-MS or ESI-MS, while the absence of un-
desired mutations was also confirmed by sequencing the
cloned KLK cDNA fragment before yeast transformation
[17,36,37]. Mature rKLK6 was used for hen immunization.Hen immunization
Laying hens (Leghorn hybrids) 3-month old were immu-
nized by subcutaneous injections on the neck. The
immunogen, rKLK6, was injected (100 μg per injection)
as an emulsion (1:1 v/v) in Complete Freund’s Adjuvant.
rKLK6 encompasses the aminoacid residues 22–244 of
the Uniprot sequence Q92876, thus corresponds to the
full-length KLK6 protein. Booster injections were admi-
nistered every 2 weeks for a total of 3 months. Care of
animals was in accordance with European legislation
and our Institution’s Guidelines pertaining to the use of
laboratory animals.Isolation of IgYs
IgYs were isolated from egg yolk according to a modified
version of the acidified water dilution method [28,38].
Briefly, yolks from 15 eggs were separated from white,
washed with distilled water and allowed to drip through
pharmaceutical gauze into a beaker. Yolk was diluted
ten times (v/v) with acidified water (pH 5.2), the mixture
was remained 16 h at 4°C and, then, centrifuged at
8,500xg for 30 min at 4°C. Lipid-containing residue was
discarded and supernatant was collected. Na2SO4 was
added to the supernatant up to 19% concentration and
the mixture remained at 37°C for 3 h and, then, at room
temperature for 16 h. Subsequently, the mixture was
centrifuged at 8,500xg for 30 min at 25°C and the
precipitant containing IgYs (100 mg/egg determined
by Bradford assay) was collected, dialyzed against water
(72 h, 4°C, MWCO of 12 kDa) and lyophilized (100 mg/
egg determined by Bradford assay). 3 mg of IgYs were
dissolved in 1 ml PBS and stored in aliquots at −20°C.
Cell culture and preparation of cell lysates and
supernatants
All cell lines were grown as described [18]. For prepar-
ation of cell lysates, cells were lysed in 50 mM Tris–
HCl, pH 8.0, 150 mM NaCl, 1% Igepal CA-630 for
30 min on ice and lysates were clarified by centrifugation
at 16,000xg for 10 min and used immediately for ana-
lysis. Serum-free conditioned media (SFCM) were col-
lected from confluent cultures at 24 h, clarified by
centrifugation and concentrated by 10-fold using centri-
fugal filter devices (Amicon, MWCO of 10 kDa).
Western blot
Samples were resolved on 12% SDS-PAGE and transferred
onto PVDF membranes. Membranes were blocked with 5%
milk in PBS. IgYs (or rabbit IgGs) was added to 1:2,500 di-
lution in 1% milk in PBS containing 0.05% Tween (PBST)
for 1 h at room temperature. Then, membranes were
washed with PBST and anti-IgY (Sigma) was added to
1:3,000 dilution in 1% milk in PBST for 1 h at room
temperature. Specific immunoreactive bands were detected
with West Pico ECL (Pierce). For immunoprecipitation,
rKLK6 (2 μg of rKLK6 in 800 μl PBS) was pre-incubated
with 20 μg of IgYs for 1 h at room temperature, then, a
rabbit anti-IgY polyclonal antibody (10 μg) was added and
the mixture incubated for another 1 h at room temperature.
Finally, 50 μl of protein G beads (1:1) were added and incu-
bated for 16 h at 4°C. Beads were recovered by centrifuga-
tion, proteins eluted in sample buffer and analyzed by
Western.
Titration ELISA
ELISA microtiter plates were coated with rKLK6 (100 ng/
ml, 100 μl/microwell, 16 h at 37°C), then, washed and
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temperature). Blocking was discarded and wells were
washed with PBST and incubated with serial dilutions of
IgYs in PBST containing 0.2% BSA (100 μl/well, 2 h at
37°C). Following, wells were washed with PBST and
incubated with rabbit anti-IgY secondary antibody
coupled to horseradish peroxidase (HRP) at 1:5,000 di-
lution in PBST with 0.2% BSA (100 μl/well, 2 h at 37°C).
Finally, wells were washed with PBST, incubated with
ABTS/H2O2 (100 μl/well, 30 min at room temperature)
and the absorbance was measured at 405 nm.
Displacement ELISA
Microtiter plates were coated and blocked as described
above. Then, microwells were incubated with varying
concentrations of anti-KLK6 IgYs concomitantly with a
series of KLK6 standard solutions. After incubation the
plates were processed as described for titration ELISA.
Enzyme kinetics
The enzymatic activity of rKLK6 [37] was measured
using the N-benzoyl-L-arginine ethyl ester (BAEE) sub-
strate in 67 mM Na2HPO4, pH 7.6. For KLK6 enzyme
kinetics, rKLK6 (R80Q) was used, a mutant form of
KLK6 with stabilized activity compared to wild-type that
is amenable to autocatalytic inactivation via cleavage at
R80 [37]. Rates of hydrolysis were measured based on
changes in the absorbance at 254 nm monitored by a
double beam UV–vis spectrophotometer (Perkin Elmer).
As control for specific inhibition of KLK6 activity, the E24
anti-KLK6 blocking mouse monoclonal was used [16]. For
inhibition assays, the antibodies were pre-mixed with
rKLK6 and incubated for 1 min, then, substrate was added
and the rate of hydrolysis was monitored.
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